You are here

IllExcor Therapeutics LLC

Company Information
Address
800 E Leigh St Ste 19
Richmond, VA 23219-1599
United States



Information

UEI: GFKZPH9N1VX3

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: Yes

Woman Owned: No



Award Charts




Award Listing

  1. Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier

    Amount: $745,621.00

    Acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non- cardiogenic respiratory failure and hypoxemia. Consequently, patients with ARDS have severe hyp ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy

    Amount: $976,740.00

    Sickle Cell Disease (SCD) affects ~100,000 individuals in the US and millions more worldwide. The disease causes a range of adverse pathophysiological effects resulting in painful crises, organ failur ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  3. Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier

    Amount: $298,412.00

    Acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non- cardiogenic respiratory failure and hypoxemia. Consequently, patients with ARDS have severe hyp ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  4. Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease

    Amount: $299,962.00

    In this SBIR Phase I project, IllExcor Therapeutics proposes the development and evaluation of novel prodrug therapeutics as a yet untapped approach to treat sickle cell disease (SCD), a hereditary ma ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  5. Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy

    Amount: $300,000.00

    Sickle cell disease (SCD), which results from a genetic mutation in hemoglobin (Hb) that causes red blood cells (RBCs) to become malformed and rigid (‘sickled’), affects approximately 100,000 Amer ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government